Mochi Moves To Dismiss, Says Lilly Does Not Allege Facts For Conspiracy Claims
SAN FRANCISCO — A telehealth company and a pharmacy that sell a compounded version of tirzepatide, a U.S. Food and Drug Administration-approved drug for diabetes and weight loss, argue in a...To view the full article, register now.
Already a subscriber? Click here to view full article